Form 4: Cidara Therapeutics CFO Sells Shares to Cover Tax Obligations

Cidara Therapeutics CFO Preetam Shah sold 18,931 shares of common stock on March 11, 2024, to cover tax withholding obligations related to the vesting and settlement of RSUs.

Summary

• On March 11, 2024, Preetam Shah, CFO & CBO of Cidara Therapeutics, Inc., sold 18,931 shares of common stock at a weighted average price ranging from $0.66 to $0.67.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• Following the transaction, Shah directly owns 227,210 shares of Cidara Therapeutics common stock, which includes 8,000 shares acquired through the company's Employee Stock Purchase Plan (ESPP) on May 19, 2023, and November 20, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects a routine transaction to cover tax obligations, which is not inherently positive or negative.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency when company insiders trade their company's stock. This filing indicates that the CFO sold shares to cover tax obligations, which is a common practice.

Comparison to Industry Standards

• Insider sales to cover tax obligations are a common practice across publicly traded companies.
• It is typical for executives to sell a portion of their vested shares to meet tax liabilities, rather than indicating a lack of confidence in the company's future prospects.
• Similar transactions can be observed in companies like Pfizer, Amgen, and Gilead Sciences, where executives periodically sell shares for tax planning purposes.

Stakeholder Impact

• The sale of shares by an insider could create short-term selling pressure on the stock.
• The transaction is unlikely to have a significant long-term impact on the company's operations or financial health.

Key Dates